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Introduction
We previously reported that radiotherapy was useful for
the treatment of mucosa-associated lymphoid tissue (MALT)
lymphoma of the ocular adnexa1). MALT lymphoma was
first described by Isaacson and Wright in 1983 as an extranodal
B-cell lymphoma arising in the marginal zone of mucosa-
associated lymphoid tissue and was established in the new
WHO classification2-3). Radiotherapy is useful for the treat-
ment of MALT lymphoma of the ocular adnexa and is the
first choice for this disease. We investigated the long-term
follow-up results of radiotherapy for MALT lymphoma of
the ocular adnexa.
Methods and Materials
Twenty-one patients with MALT lymphoma of the ocu-
lar adnexa treated with radiotherapy alone at Hiroshima
Prefectural Hospital between 1998 and 2010 were retro-
spectively analyzed (Table 1). In 15 patients the disease
arose from the conjunctiva, and in 6 patients, it originated
from the retrobulbar space. Bilateral conjunctival involve-
ment was found in 9 patients, and involvement of the bilat-
eral retrobulbar space was found in 1 patient.
The median follow-up of the surviving patients was 86
months (range, 11-157).
The histological diagnoses obtained via an incisional bi-
opsy in all cases were categorized according to the criteria
Acta Med. Nagasaki 56: 49－52
Address correspondence: Yoshio Monzen, M.D. Department of Radiology, Hiroshima Prefectural Hospital,
1-5-54 Ujinakanda Minami-ku, Hiroshima 734-8530 Japan
TEL:+81-082-254-1818, Ext. 1000, FAX:+81-082-253-8274, E-mail:monzen.so@s9.dion.ne.jp
Received May 12, 2011; Accepted July 12, 2011
MS#AMN 07086
Radiotherapy for mucosa-associated lymphoid tissue lymphoma
of the ocular adnexa
Yoshio MONZEN1, Koichi WADASAKI1, Haruyuki HASEBE2, Takashi NISHISAKA3, Toshiyuki FUKUHARA3
1 Department of Radiology, Hiroshima Prefectural Hospital
2 Department of Ophthalmology, Hiroshima Prefectural Hospital
3 Department of Pathology, Hiroshima Prefectural Hospital
Objectives: We investigated the results of radiotherapy for mucosa-associated lymphoid tissue (MALT) lymphoma of the
ocular adnexa.
Methods: Twenty-one patients with MALT lymphoma of the ocular adnexa were treated with radiotherapy alone at a dose
ranging from 30 to 54Gy. The disease arose from the conjunctiva in 15 patients (9 with bilateral involvement), and from the
retrobulbar space in 6 patients (1 with bilateral involvement).
Results: All patients with MALT lymphoma achieved a CR or unconfirmed CR (CRu). The 5-and 10-year overall survival
rates of all patients with MALT lymphoma were 100% and 90%, respectively. The 5-and 10-year cause-specific survival rates
were 100% and 100%, respectively. In all patients with delayed toxicity, the radiation dose was more than 40Gy.
Conclusions: Excellent local control and survival can be achieved for patients with MALT lymphoma of the ocular adnexa
using radiotherapy alone.
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established by the WHO classification. During the staging
work-up, gallium scans, computed tomography of the chest
and abdomen, and FDG-PET were performed for all patients.
Patients with I AE or I AE2 disease according to the American
Joint Committee on Cancer TNM Classification were treated
with radiotherapy alone (Table 2)4). Lesions confined to the
conjunctiva were treated with a single anterior direct field
using a 6-12 MeV electron beam. The entire bulbar and
palpebral conjunctiva were treated. Retrobulbar tumors were
irradiated with 18 MeV electron or 6-MV X-rays. The clinical
target volume was the entire orbital cavity. The field ar-
rangement was the anterior field, wedged anterior and oblique
fields, or opposing lateral fields. A median dose per frac-
tion of 2.0Gy (range 1.8-2.5) was administered, with the
total dose ranging between 30 and 54Gy (median, 38Gy).
Lead eye shields were used for radiotherapy of conjunctival
lymphoma. Lens protection was not used for radiotherapy
of retrobulbar lymphoma except for one patient (case 16).
Complete regression of the tumor mass after treatment was
considered a complete remission (CR). The absence of
regrowth after a follow-up period of more than 3 months
indicated an unconfirmed CR (CRu)5).
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Table 1. Characteristics of 21 patients with ocular-
adnexal MALT lymphoma
































































48 R, 40 L
41.5 R, 50 L
40
40 R, 40 L
38
38 R, 38 L
38 R, 38 L
38 R, 38 L
38 R, 38 L
36
38
30.6 R, 30.6 L
30.6
30.6
30.6 R, 30.6 L
40
54

























28d R, 28d L
10d R, 8m L
26d
0d R, 0d L
1m
9m R, 39d L
0d R, 8m L
3m R, 3m L


































Table 2. Treatment methods and results
R=right eye, L=left eye, I.D.C.L=interval of disappearance of conjunctival lymphoma, m=month, d=day
*=Although local retrobulbar lymphoma disappeared, a right submandibular mass 21 months after radiotherapy.
Histological examination of the resected mass showed follicular, mixed, B cell type lymphoma.
NED=no evidence of disease DOOD=die of other disease
NA=data not available
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Results
Fifteen patients with conjunctival lymphoma achieved a
CR. There have been no signs of recurrence or metastasis
in any of these patients, with a follow-up ranging from 11
to 157 months after treatment (Table 2). Conjunctival lym-
phoma disappeared within 14 months after therapy.
Six patients with lesions of the retrobulbar space achieved
a CR or CRu. There have been no signs of recurrence or
metastasis in any of these patients, with follow-up ranging
from 67 to 139 months after treatment. Two patients died
of other diseases. One patient died of lung cancer (case 16),
and another patient died of progressive supranuclear palsy
(case 19). Although local retrobulbar lymphoma disappeared,
a right submandibular mass was observed 21 months after
radiotherapy in case 21. The patient underwent a tumorectomy.
A histological examination of the resected mass showed a
follicular mixed B cell type lymphoma. The 5-and 10-year
overall survival rates of all patients with MALT lymphoma
were 100% and 90%, respectively (Fig. 1). The 5-and 10-
year cause-specific survival rates were 100% and 100%, re-
spectively (Fig. 2).
Seven eye-balls developed delayed toxicity (Table 3).
Four eye-balls with conjunctival lymphoma experienced dry
eye syndrome, and four eye-balls developed cataracts. One
patient with retrobulbar lymphoma experienced both dry
eye syndrome and cataracts (case 16). The vision of pa-
tients with cataracts was restored by surgery. In seven eye-
balls, the radiation dose had been 40Gy or more.
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Fig. 1. Overall survival rate
Fig. 2. Cause-specific survival rate






















































Table 3. Summary of delayed toxicity
(+) : the interval between radiotherapy and diagnosis of dry eye syndrome.
[+] : the interval between radiotherapy and operation for cataract.
DES=dry eye syndrome m=month
R=right eye, L=left eye
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Discussion
Most MALT lymphomas originate from the stomach and
lung, which represents 5-16% of malignant lymphomas.
Orbital MALT lymphoma accounts for 11-27% of MALT
lymphomas6-8).
In all of the present cases, MALT lymphoma of the ocu-
lar adnexa was well-controlled after radiotherapy. Suh et al.
reported 52 eye lesions with orbital MALT lymphoma that
were treated with radiotherapy. The radiation doses ranged
from 5.4 to 30.6Gy (median, 30.6Gy). Forty-six of their le-
sions showed a complete response, while the remaining six
lesions demonstrated a partial response. Three patients ex-
perienced local recurrences. The 10-year actuarial relapse-
free survival, cause-specific survival, and overall survival
rates were 93%, 98%, and 87% respectively, in that study9).
Nevertheless, when 30-54 Gy was delivered as in our study,
the local control of MALT lymphoma of the ocular adnexa
was excellent. This indicates that the tumor dose in MALT
lymphoma of the ocular adnexa does not always participate
in local control. Letschert et al. advocated a tumor dose of
30Gy with a local control rate of more than 90% achieved
for MALT lymphoma of the ocular adnexa10). Bayraktar et
al. reported that radiation doses of 30.6Gy should be given
in Ann-Arbor stageⅠdisease, since lower doses may be more
frequently associated with relapse, including CNS relapses11).
Suh et al. suggested that 30Gy may be sufficient for the
treatment of MALT lymphoma in the ocular adnexa9). A
dose of less than 30Gy does not develop dry eye syndrome
which represents the delayed adverse event of the lacrimal
gland. Dry eye syndrome develops 5-25% by a dose of 30-
40Gy, rapidly increases by a dose of more than 40 Gy, and
develops 100% by a dose of more than 57Gy12). As a dose
of more than 30Gy develops dry eye syndrome or cataract,
the dose must not exceed 30Gy for safe treatment of MALT
lymphoma of the ocular adnexa.
At present, based on our study and these previous stud-
ies, we administer a radiation dose of 30.6Gy with a frac-
tion size of 1.8Gy for MALT lymphoma of ocular adnexa
treatment.
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